BACKGROUND: Even low levels of residual symptoms are known to increase the risk of relapse and early recurrence of major depression. It is not known if ongoing psychotherapy lessens this risk. We therefore examined the impact of persistent symptoms, including mood, insomnia, and anxiety symptoms, on time to recurrence in women receiving maintenance interpersonal psychotherapy (IPT-M) for recurrent depression. METHODS: We analyzed data on 131 women aged 20-60 from a 2-year randomized trial of weekly versus twice-monthly versus monthly IPT-M. Participants achieved remission with IPT alone (n=99) or IPT plus sequential antidepressant medication (n=32). Medications were tapered before starting maintenance treatment. Residual symptoms were assessed with the Hamilton Rating Scale for Depression (HRSD; total score and subscales); insomnia was also assessed in 76 women with the Pittsburgh Sleep Quality Index (PSQI). Data analyses used Cox proportional hazards regression models. RESULTS: Neither overall burden of residual symptoms (HRSD total score), nor HRSD mood and anxiety subscale scores predicted recurrence during ongoing IPT-M. In contrast, persistent insomnia measured both by the HRSD-17 insomnia subscale and the PSQI predicted recurrence. Women with persistent insomnia who required sequential pharamacotherapy had the highest recurrence rate (65%) compared to women requiring sequential treatment without insomnia (13%), or women who had recovered with IPT alone but had persistent insomnia (21%) or no insomnia (18%). CONCLUSIONS:Persistent insomnia following the recovery from an episode of recurrent major depression is associated with increased risk of recurrence despite maintenance psychotherapy, particularly for those withdrawn from antidepressant medication.
RCT Entities:
BACKGROUND: Even low levels of residual symptoms are known to increase the risk of relapse and early recurrence of major depression. It is not known if ongoing psychotherapy lessens this risk. We therefore examined the impact of persistent symptoms, including mood, insomnia, and anxiety symptoms, on time to recurrence in women receiving maintenance interpersonal psychotherapy (IPT-M) for recurrent depression. METHODS: We analyzed data on 131 women aged 20-60 from a 2-year randomized trial of weekly versus twice-monthly versus monthly IPT-M. Participants achieved remission with IPT alone (n=99) or IPT plus sequential antidepressant medication (n=32). Medications were tapered before starting maintenance treatment. Residual symptoms were assessed with the Hamilton Rating Scale for Depression (HRSD; total score and subscales); insomnia was also assessed in 76 women with the Pittsburgh Sleep Quality Index (PSQI). Data analyses used Cox proportional hazards regression models. RESULTS: Neither overall burden of residual symptoms (HRSD total score), nor HRSD mood and anxiety subscale scores predicted recurrence during ongoing IPT-M. In contrast, persistent insomnia measured both by the HRSD-17 insomnia subscale and the PSQI predicted recurrence. Women with persistent insomnia who required sequential pharamacotherapy had the highest recurrence rate (65%) compared to women requiring sequential treatment without insomnia (13%), or women who had recovered with IPT alone but had persistent insomnia (21%) or no insomnia (18%). CONCLUSIONS: Persistent insomnia following the recovery from an episode of recurrent major depression is associated with increased risk of recurrence despite maintenance psychotherapy, particularly for those withdrawn from antidepressant medication.
Authors: Rachel Manber; A John Rush; Michael E Thase; Bruce Amow; Dan Klein; Madhukar H Trivedi; Susan G Korenstein; John C Markowitz; David L Dunner; Melvin Munsaka; Fran E Borian; B Keller Journal: Sleep Date: 2003-03-15 Impact factor: 5.849
Authors: G M Asnis; A Chakraburtty; E A DuBoff; A Krystal; P D Londborg; R Rosenberg; B Roth-Schechter; M B Scharf; J K Walsh Journal: J Clin Psychiatry Date: 1999-10 Impact factor: 4.384
Authors: A N Vgontzas; E O Bixler; H M Lin; P Prolo; G Mastorakos; A Vela-Bueno; A Kales; G P Chrousos Journal: J Clin Endocrinol Metab Date: 2001-08 Impact factor: 5.958
Authors: Michael E Thase; A John Rush; Rachel Manber; Susan G Kornstein; Daniel N Klein; John C Markowitz; Philip T Ninan; Edward S Friedman; David L Dunner; Alan F Schatzberg; Frances E Borian; Madhukar H Trivedi; Martin B Keller Journal: J Clin Psychiatry Date: 2002-06 Impact factor: 4.384
Authors: Daniel J Taylor; Heather M Walters; Jeffrey R Vittengl; Steven Krebaum; Robin B Jarrett Journal: J Affect Disord Date: 2009-09-05 Impact factor: 4.839
Authors: Greg Clarke; Eleanor L McGlinchey; Kerrie Hein; Christina M Gullion; John F Dickerson; Michael C Leo; Allison G Harvey Journal: Behav Res Ther Date: 2015-04-14
Authors: Eleanor L McGlinchey; Jazmin A Reyes-Portillo; J Blake Turner; Laura Mufson Journal: Child Adolesc Ment Health Date: 2016-06-30 Impact factor: 2.175
Authors: Leslie M Swanson; Edward D Huntley; Holli Bertram; Ann Mooney; Richard Dopp; Robert Hoffmann; Roseanne Armitage; J Todd Arnedt Journal: Behav Sleep Med Date: 2016-08-05 Impact factor: 2.964